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Background: To compare the safety and efficacy of saxagliptin 2.5 mg twice daily (BID) versus placebo add-on
therapy to metformin immediate release (IR) in patients with type 2 diabetes and inadequate glycemic control with
metformin alone.
Methods: This multicenter, 12-week, double-blind, parallel-group trial enrolled adult outpatients with type 2 diabetes
(glycated hemoglobin [HbA1c] 7.0%–10.0%) on stable metformin IR monotherapy (≥1500 mg, BID for ≥8 weeks). Patients
were randomized to double-blind saxagliptin 2.5 mg BID or placebo added on to metformin IR following a 2-week,
single-blind, placebo add-on therapy lead-in period. The primary end point was the change from baseline to week 12 in
HbA1c. Key secondary end points included change from baseline to week 12 in fasting plasma glucose (FPG) and the
proportion of patients achieving HbA1c <7.0% or HbA1c≤ 6.5% at week 12. Efficacy was analyzed in all patients who
received randomized study drug with ≥1 postbaseline assessment. Safety was assessed in all treated patients.
Results: In total, 74 patients were randomized to double-blind saxagliptin add-on therapy and 86 to placebo add-on
therapy. At week 12, least-squares mean changes (95% CI) from baseline HbA1c (adjusted for baseline HbA1c) were
significantly greater (P= 0.006) in the saxagliptin +metformin group −0.56% (−0.74% to −0.38%) versus the placebo +
metformin group −0.22% (−0.39% to −0.06%). Adjusted mean changes from baseline in FPG were numerically greater with
saxagliptin versus placebo; the difference (95% CI) −9.5 mg/dL (−21.7 to 2.7) was not statistically significant (P = 0.12). A
numerically greater proportion of patients in the saxagliptin group than the placebo group achieved HbA1c < 7.0% (37.5%
vs 24.2%) or HbA1c ≤6.5% (24.6% vs 10.7%). There were no unexpected safety findings. Hypoglycemia occurred in 4
patients (5.4%) in the saxagliptin group and 1 patient (1.2%) in the placebo group; confirmed hypoglycemia (symptoms
plus fingerstick glucose ≤50 mg/dL) occurred in 1 patient in the placebo group.
Conclusions: Addition of saxagliptin 2.5 mg BID to metformin therapy in patients with type 2 diabetes and inadequate
glycemic control on metformin monotherapy reduced HbA1c compared with placebo added to metformin, with an
adverse events profile similar to placebo and no unexpected safety findings.
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Type 2 diabetes is a progressive disease with multiple factors
contributing to hyperglycemia—insulin resistance in muscle,
liver, and adipose tissue, increased hepatic glucose produc-
tion, and decreased insulin secretion [1]. Adequate glycemic
control may not be possible with lifestyle interventions or
medication therapy with a single agent [1,2]. Although met-
formin addresses some of the primary defects in insulin re-
sponse (decreases hepatic glucose production and improves
insulin sensitivity) [1,2] and is considered first-line pharma-
cologic treatment for type 2 diabetes [2,3], the American
Diabetes Association and other guidelines recommend com-
bination therapy when glycated hemoglobin (HbA1c) goal
(<7% or ≤6.5%) [2-4] is not achieved or maintained over a
3- to 6-month period [2]. In addition, combination therapy
may be appropriate as initial therapy for patients with high
baseline HbA1c (>7.5% or ≥9.0%) [2,4].
Because of the eventual need for combination therapy in
most patients with type 2 diabetes, as well as the high
prevalence of comorbidities, polypharmacy is common,
and the pill burden is high [5]. Adherence to oral antihy-
perglycemic therapy is diminished in patients taking mul-
tiple tablets compared with those taking 1 tablet per day
[6]. Cheong et al. reported significantly higher adherence
to oral antidiabetic therapy in patients with type 2 diabetes
using fixed-dose combination therapy versus separate-pill
dual therapy; switching to fixed-dose combination therapy
was associated with a 12% increase in adherence (assessed
as the medication possession ratio) compared with a 5% in-
crease for those maintaining separate-pill dual therapy [7].
Saxagliptin is a dipeptidyl peptidase-4 (DPP-4) inhibi-
tor that inhibits degradation of the incretin hormones
glucagon-like peptide-1 and glucose-dependent insulino-
tropic peptide, complementing the actions of metformin
by reducing postprandial hyperglycemia, enhancing insulin
secretion, and inhibiting paradoxical increased postpran-
dial glucagon secretion [1,8]. Saxagliptin is approved as an
adjunct to diet and exercise, as monotherapy or as an ini-
tial combination with metformin, to improve glycemic
control in adults with type 2 diabetes (United States)
[9,10]. It is also approved for use as combination therapy
with metformin, a sulfonylurea, a thiazolidinedione, or in-
sulin, when these agents alone, with diet and exercise, do
not provide adequate glycemic control in adults with type
2 diabetes (United States and European Union) [11].
Randomized double-blind studies have evaluated the ef-
ficacy and safety of once-daily (QD) saxagliptin as add-on
therapy to metformin in patients with type 2 diabetes and
inadequate glycemic control receiving metformin alone
[12-17]. For example, a 24-week trial in 743 patients dem-
onstrated significant reductions in HbA1c and fasting
plasma glucose (FPG) with saxagliptin (2.5 mg, 5 mg, or
10 mg QD) plus metformin immediate release (IR) in di-
vided daily doses versus placebo with metformin [12]. Inanother 24-week study, 286 patients with inadequate gly-
cemic control on sub-maximal metformin IR received
fixed-dose metformin IR (1500 mg/day) plus add-on saxa-
gliptin 5 mg/day or a 2-step uptitration to a maximum
dose of metformin IR (2500 mg/day) [13]. The change
from baseline in HbA1c at 24 weeks was similar between
the 2 treatment groups. An 18-week trial in 282 patients
demonstrated superior glycemic control with saxagliptin
5 mg added to extended-release (XR) metformin 1500 mg
(once per evening meal) compared with increasing met-
formin XR to 2000 mg [14]. A 4-week trial in 93 patients
revealed significantly greater reductions in 24-hour mean
weighted plasma glucose in patients randomized to saxa-
gliptin 5 mg once daily plus metformin XR (in divided
daily doses) compared with those in the placebo plus met-
formin group [15]. In 2 randomized, double-blind studies
comparing saxagliptin versus sitagliptin and versus glipi-
zide as add-on therapy to metformin IR in divided daily
doses, the improvement in glycemic control was similar
with saxagliptin 5 mg and sitagliptin 100 mg over 18 weeks
[16] and glipizide 5–20 mg/day (based on uptitration, as
needed) over 52 weeks [17].
In addition, a 24-week randomized controlled trial with
a 52-week extension evaluating saxagliptin 5 or 10 mg
plus metformin IR as initial combination therapy in
treatment-naive patients with type 2 diabetes demon-
strated a significant and durable improvement in glycemic
control with combination therapy versus either monother-
apy [18,19]. Across these studies, saxagliptin plus metfor-
min has demonstrated a favorable safety profile, with low
incidences of hypoglycemia and treatment-related adverse
events (AEs).
Fixed-dose combination products containing DPP-4 in-
hibitors and metformin are desirable to physicians as a
means to potentially improve patient adherence compared
with separate-pill dual therapy [20]. The current recom-
mended dose of saxagliptin in the European Union and
other markets is 5 mg QD [10]. This study investigated
the safety and efficacy of saxagliptin taken as a divided
dose of 2.5 mg twice daily (BID) in combination with met-
formin IR BID in patients with inadequate glucose control
on metformin alone. With metformin IR typically given
BID, a study evaluating saxagliptin using the same dosage
schedule for both drugs would provide clinical data in




This was a randomized (1:1), multicenter, parallel-group
trial (outpatient setting) comparing saxagliptin 2.5 mg
BID versus placebo BID as add-on therapy to metformin
IR BID (ClinicalTrials.gov registration: NCT00885378.
The study took place at 25 sites in the United States, 9
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Rico. The protocol, amendments, and patient informed
consent were approved by the institutional review board
(IRB)/independent ethics committee (IEC) at each site
before study initiation, and the study was performed in
accordance with the Declaration of Helsinki and the Inter-
national Conference on Harmonisation/Good Clinical
Practice. Patients provided informed consent before study
participation. Each IRB/IEC was composed of a review
panel that was responsible for ensuring the protection of
the rights, safety, and well-being of human subjects in-
volved in the clinical investigation and was adequately
constituted to provide assurance of that protection.Eligibility
Patients were men and nonpregnant nonlactating women
aged 18 to 78 years receiving stable metformin IR mono-
therapy (daily dose ≥1500 mg, given BID) for ≥8 weeks
before enrollment and having inadequate glycemic con-
trol (HbA1c level 7.0%–10.0% with diet and exercise).
Additional inclusion criteria were a fasting C-peptide
value ≥0.8 ng/mL and body mass index (BMI) ≤45.0 kg/
m2. Patients were excluded if they had marked polydipsia
and polyuria with >10% weight loss <3 months before
screening, history of diabetic ketoacidosis or hyperosmolar
nonketotic coma, or insulin therapy (except during short-
term hospitalization or gestational diabetes) within 1 year
of screening. Additional exclusion criteria included a
cardiovascular event within 3 months of screening,
congestive heart failure New York Heart Association
class III/IV, known ejection fraction ≤40%, or history of
hemoglobinopathies.Treatment
Patients were enrolled by investigators at each study site.
At the screening visit, each patient was assigned a
unique sequential subject number by an Interactive Voice
Response System (IVRS), which was used for identification
throughout the study. After a 2-week single-blind lead-
in period with placebo BID added to metformin IR BID
(with diet and exercise), patients were randomized 1:1
to 12 weeks of double-blind treatment with saxagliptin
2.5 mg BID or matching placebo BID added on to
metformin IR using a blocked randomization schedule.
The computer-generated randomization scheme was de-
veloped and kept by the study sponsor. Randomization
was performed by calling the IVRS. Placebo tablets
were identical in appearance to the saxagliptin tablets,
and medication was dispensed using bottle numbers
assigned by the IVRS. Titration or adjustment of
blinded saxagliptin or metformin was not allowed dur-
ing the study.Assessments
The primary end point was the change in HbA1c from
baseline to week 12 (or last observation carried forward
[LOCF], if no week-12 value was available). Key secondary
end points were FPG change from baseline to week 12,
proportion of patients achieving HbA1c <7.0% at week 12,
and the proportion of patients achieving HbA1c ≤6.5% at
week 12. Other efficacy variables included the proportions
of patients with 1) reductions in HbA1c ≥0.5% or 2) ≥0.7%,
3) with FPG <110 mg/dL or 4) FPG <126 mg/dL, and 5)
proportions requiring discontinuation for lack of glycemic
control (FPG ≥270 mg/dL at 4 weeks or ≥240 mg/dL at
8 weeks). Body weight was evaluated post hoc as an ex-
ploratory end point.
Safety assessments included AEs, electrocardiograms,
vital signs, physical exams, and clinical laboratory tests
(ie, hematology, serum chemistry [liver function, kidney
function, creatinine kinase, electrolytes, protein], and
urine testing).
Data analysis/statistics
Baseline and change from baseline efficacy assessments
were analyzed in the Randomized Patients Population
(those who received randomized study drug with ≥1 post-
baseline assessment). The primary efficacy analysis was an
analysis of covariance (ANCOVA) of the adjusted mean
change in HbA1c (least-squares mean adjusted for baseline
HbA1c value) from baseline to week 12 (or LOCF) during
the double-blind period with treatment as a fixed effect
and baseline HbA1c as a covariate. A sample size of 152
(n = 76 per treatment group) was calculated to provide
90% power to detect an estimated 0.6% difference in
HbA1c with SD of 1.1%, assuming 5% of patients were
unevaluable and a 2-sided α of 0.05. In addition, sub-
groups of HbA1c, gender, age and ethnicity were also ana-
lyzed by ANCOVA similar to the primary analysis.
Change from baseline to week 12 in FPG was analyzed in
the same way as the primary end point. The number and
proportion of patients achieving a therapeutic glycemic re-
sponse (HbA1c <7.0%) at week 12 LOCF was compared be-
tween groups using the methodology of Zhang et al. [21]
and Tsiatis et al. [22]. A similar analysis was conducted for
the proportion of patients achieving HbA1c ≤6.5% at week
12. As a post hoc analysis, mean (95% CI) changes in body
weight (LOCF) from baseline to week 12 were summarized
by treatment group. Other efficacy end points were analyzed
using descriptive statistics (n [%]).
The protocol specified the sequential testing approach
to control the type I error rate at the 0.05 level. Once an
end point failed to achieve statistical significance, subse-
quent end points in the sequence were assessed using only
summary statistics, including the 95% CI. The order of
testing was 1) primary end point, 2) change from baseline
in FPG, 3) proportion of patients with HbA1c <7.0% at
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at week 12. Statistical analyses were performed using SAS
Version 8.2 or higher (SAS Institute Inc., Cary, NC).
Safety analyses were conducted using the Treated Pa-
tients Population that comprised all patients who received
study drug during the double-blind treatment period.
Clinical AEs were summarized using Medical Dictionary
for Regulatory Activities (MedDRA) version 12.1. Events
of special interest were based on a list of predefined




The study was initiated on May 13, 2009 and ended on
February 24, 2010 (data collection complete); recruitment
took place between May 13, 2009 and November 13,
2009. A total of 160 patients were randomized to saxaglip-
tin (n = 74) or placebo (n = 86) as add-on therapy to
metformin IR and received ≥1 dose during the double-
blind phase (Figure 1). All were included in the Randomized
Patients Population (efficacy analysis) and the Treated Pa-
tients Population (safety analysis), and analyses were by ran-
domized treatment group. Of those randomized and treated
with drug, 144 patients (saxagliptin, n = 66; placebo, n = 78)
completed 12 weeks of treatment. A similar proportion of
patients in both treatment groups (saxagliptin 10.8%,Figure 1 Patient disposition. *Did not satisfy study inclusion and exclusion
(later classified as a serious AE, requiring hospitalization). ‡Values did not mee
patient for safety reasons.placebo 9.3%) discontinued from the trial. The most com-
mon reasons for discontinuation were insufficient glycemic
control (2 subjects each group: saxagliptin 2.7%; placebo
2.3%) and poor/noncompliance (2 subjects each group: sax-
agliptin 2.7%; placebo 2.3%). Patient characteristics are
shown in Table 1; 90% were white, 40% were Hispanic or
Latino, and the mean (SD) duration of type 2 diabetes was
6.0 (5.30) years.
Extent of exposure
Mean (SD) duration of exposure to study drug was 80.8
(14.55) days for the saxagliptin plus metformin group
and 79.7 (17.46) days for the placebo plus metformin
group; >80% of patients per group continued study
medication for ≥82 days.
Efficacy
At week 12, adjusted mean reductions (95% CI) from
baseline in HbA1c were significantly greater (P = 0.006)
in the saxagliptin plus metformin group (−0.56% [−0.74
to −0.38]) versus the placebo plus metformin group
(−0.22% [−0.39 to −0.06]) (Table 2). There was a pro-
gressive decrease in HbA1c to −0.56% in the saxagliptin
group throughout the duration of the study (Figure 2A).
There were no interactions observed for change from
baseline in HbA1c and treatment by baseline HbA1c,
gender, age, or ethnicity.criteria. †Abdominal pain secondary to partial small bowel obstruction
t the exclusion criteria; however, the investigator chose to withdraw the
Table 1 Patient demographic and baseline characteristics
(randomized patients population)
Characteristic Saxagliptin +
Metformin (n = 74)
Placebo +
Metformin (n = 86)
Men, n(%) 40 (54.1) 45 (52.3)
Mean (SD) age, y 53.9 (10.35) 56.6 (9.97)
Race, n(%)
White 64 (86.5) 80 (93.0)
Black/African
American




Asian 2 (2.7) 2 (2.3)
Ethnicity, n(%)
Hispanic or Latino 29 (39.2) 35 (40.7)
Not Hispanic or
Latino
34 (45.9) 36 (41.9)
Not reported 11 (14.9) 15 (17.4)
BMI, kg/m2
Mean (SD) 33.7 (5.94) 32.5 (6.18)
Median (range) 33.8 (19.89–44.95) 31.1 (20.68–44.64)
Mean (SD) duration of
type 2 diabetes, y
5.8 (6.37) 6.2 (4.21)
Mean (SD) HbA1c,% 7.92 (0.961) 7.97 (0.819)
Mean (SD) FPG, mg/dL 164.9 (47.16) 161.5 (41.71)
Metformin dose (mg),
n(%)
1500– <2000 28 (37.8) 35 (40.7)
2000– <2500 38 (51.4) 45 (52.3)
≥2500 8 (10.8) 6 (7.0)
BMI = body mass index; FPG = fasting plasma glucose;
HbA1c = glycated hemoglobin.
Table 2 Primary and key secondary end points (randomized p
Efficacy variable Saxagliptin + Metformin (n = 74)
HbA1c ,% n = 74
Baseline mean (SE) 7.92 (0.11)
Week 12* mean (SE) 7.36 (0.13)
Week 12* adjusted mean
change from baseline (SE)
−0.56 (0.09)
FPG, mg/dL n = 73
Baseline mean (SE) 164.22 (5.51)
Week 12* mean (SE) 149.74 (6.18)
Week 12* adjusted mean
change from baseline (SE)
−13.73 (4.51)
Patients achieving HbA1c levels n = 74
HbA1c <7%, n (%) 29 (37.5)
HbA1c ≤6.5%, n (%) 19 (24.6)
FPG = fasting plasma glucose; HbA1c = glycated hemoglobin.
*Using last observation carried forward, applying the last postbaseline value when
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the first secondary end point, FPG, were numerically greater
(−13.73 mg/dL) in the saxagliptin plus metformin group
than in the placebo plus metformin group (−4.22 mg/dL)
(Figure 2B), though the difference (95% CI) of −9.5 mg/
dL (−21.7 to 2.7) at week 12 was not statistically significant
(P= 0.12) (Table 2). Accordingly, subsequent secondary end
points were analyzed using only summary statistics.
The percentage of patients achieving a therapeutic gly-
cemic response (HbA1c <7%) was numerically greater with
saxagliptin plus metformin versus placebo plus metformin
(37.5% [29/74] vs 24.2% [19/84]). The difference (95% CI)
in the proportions of patients achieving HbA1c <7% versus
placebo was 13.2% (1.1 to 25.4). Numerically more pa-
tients in the saxagliptin plus metformin group than the
placebo plus metformin group achieved HbA1c ≤6.5%
(24.6% [19/74] vs 10.7% [8/84]; Table 2). The difference in
the proportions of patients achieving HbA1c ≤6.5% versus
placebo was 13.8% (3.0 to 24.7).Other parameters relevant to efficacy
At week 12, a reduction in HbA1c of ≥0.5% was achieved by
51.4% (38/74) and 36.9% (31/84) of patients in the
saxagliptin plus metformin group and the placebo plus met-
formin group, respectively (difference [95% CI], 16.8% [2.3
to 31.3]). A reduction of ≥0.7% was achieved by 40.5% (30/
74) and 23.8% (20/84), respectively (difference [95% CI],
14.6% [0.8 to 30.1]).
At week 12, in the saxagliptin plus metformin group
and the placebo plus metformin group, 19.2% (14/73)
and 3.6% (3/84), respectively, achieved FPG <110 mg/dL,
and 37.0% (27/73) and 16.7% (14/84) of patients, re-
spectively, achieved FPG <126 mg/dL.atients population)












week 12 values were unavailable.
Figure 2 Mean change from baseline HbA1c and fasting plasma glucose (FPG). A. Mean (SE) change from baseline HbA1c during the
double-blind treatment period. BID = twice daily; HbA1c = glycated hemoglobin; SAXA = saxagliptin. Mean (SE) baseline values were 7.92% (0.11)
in the saxagliptin group and 7.97% (0.09) in the placebo group. B. Mean (SE) change from baseline fasting plasma glucose (FPG) during the
double-blind treatment period. BID = twice daily; FPG = fasting plasma glucose; SAXA = saxagliptin. Mean (SE) baseline values were 164.22 mg/
dL (5.51) in the saxagliptin group and 161.25 mg/dL (4.62) in the placebo group.
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cause of lack of glycemic control at week 4 (saxagliptin
plus metformin, n = 1, 1.4%; placebo plus metformin, n = 1,
1.2%) and week 8 (saxagliptin plus metformin, n = 2, 2.7%;
placebo plus metformin, n = 1, 1.2%).Overall, there were reductions in mean body weight
(LOCF) in both treatment groups. Mean change in body
weight (95% CI) at week 12 was −0.32 kg (−0.97 to 0.34)
for the saxagliptin plus metformin group and −0.40 kg
(−0.83 to 0.02) for the placebo plus metformin group.
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During the double-blind period, the proportion of patients
reporting ≥1 AE (irrespective of investigator-assessed rela-
tionship to treatment) was 25.7% (19/74) for the saxaglip-
tin plus metformin group and 39.5% (34/86) for the
placebo plus metformin group (Table 3). Treatment-
related AEs as identified by the blinded investigator assess-
ment occurred in 1 patient (1.4%) in the saxagliptin plus
metformin group (nausea and dizziness; mild in severity)
and 3 patients (3.5%) in the placebo plus metformin
group (fatigue, increased blood creatine phosphokinase,
and insomnia); no deaths occurred in either group dur-
ing the 12-week double-blind treatment period
(Table 3). Apart from hypoglycemia (described below),
the most common AEs in the saxagliptin plus metformin
group were back pain (2.7% vs 3.5% for placebo plus met-
formin), hypertension (2.7% vs 2.3%), dizziness (2.7% vs 0),
and lymphadenopathy (2.7% vs 0; Table 4). Events with
higher incidences in the placebo plus metformin group
versus the saxagliptin plus metformin group were gastro-
intestinal (GI) AEs at the system organ class level (saxaglip-
tin, 4.1%; placebo, 7.0%) and diarrhea (1.4% versus 3.5%).
One patient in each treatment group experienced ≥1 ser-
ious AE (saxagliptin: myocardial infarction and pulmonary
edema; placebo: severe back pain requiring hospitalization,
owing to a lumbar strain); neither of these was considered
treatment related.
Confirmed hypoglycemia, defined by hypoglycemic symp-
toms plus a fingerstick glucose value ≤50 mg/dL, occurred
in only 1 patient (placebo plus metformin group) during the
double-blind period. Hypoglycemia occurred in 4 patients
(5.4%) in the saxagliptin plus metformin group and 1 patient
(1.2%) in the placebo plus metformin group during double-
blind treatment; all were rated mild or moderate in severity.
There were no events of serious hypoglycemia, and no pa-
tient discontinued the study owing to hypoglycemia during
double-blind treatment. Other categories of AEs were iden-
tified as being of special interest based on findings observed
in the saxagliptin nonclinical and Phase 1 and 2b programs,
safety-related concerns reported for other DPP-4 inhibitors,Table 3 Patients with adverse events during the double-
blind phase (treated patients population)
n (%) Saxagliptin +
Metformin (n = 74)
Placebo +
Metformin (n = 86)
Any AE 19 (25.7) 34 (39.5)
Treatment-related AE 1 (1.4) 3 (3.5)
SAE 1 (1.4) 1 (1.2)





AE = adverse event; SAE = serious adverse event.and theoretical considerations related to the mechanism of
action of DPP-4. There were 2 such AEs, both in
saxagliptin-treated patients. A 63-year-old man, with hyper-
tension, recent death of spouse, and 9-pound weight gain
who quit smoking 10 days previously, suffered a non-ST-
segment myocardial infarction (the only confirmed major
adverse cardiovascular event [MACE] in the trial) with pul-
monary edema. A 100% right coronary artery ostial occlu-
sion with collateralization was noted, and the 80%–90%
proximal left circumflex artery lesion was treated with per-
cutaneous transluminal coronary angioplasty and a stent.
Study medication was resumed and the patient completed
the trial. A second patient experienced a severe AE of
thrombocytopenia (baseline platelet count of 102 × 103 c/
μL fell to 97 × 103 c/μL at the last study visit). The patient
was asymptomatic, and the event was deemed not related to
treatment. There were no reports of other AEs of spe-
cial interest, including skin disorders, lymphopenia,
thrombocytopenia, localized edema, hypersensitivity,
fractures, or pancreatitis. There was no clinically mean-
ingful drug effect on any other laboratory safety param-
eter, including hematologic, liver, renal, electrolytes,
protein, and musculoskeletal parameters.
Discussion
In the study reported here, saxagliptin 2.5 mg BID in
combination with metformin IR BID for 12 weeks signifi-
cantly reduced HbA1c in patients with type 2 diabetes with
inadequate glycemic control with metformin alone. Saxa-
gliptin had an AE profile similar to placebo and no unex-
pected safety findings.
Our findings add to an existing literature demonstrat-
ing that the addition of saxagliptin to metformin therapy
improves glucose control in patients with type 2 dia-
betes. Across 3 previous trials of saxagliptin 5 mg QD as
add-on therapy in patients with inadequate glycemic
control on metformin IR monotherapy, adjusted mean
changes from baseline HbA1c were −0.52% (18-week trial
of saxagliptin versus sitagliptin as add-on therapy to
metformin) [16], −0.69% (24-week trial of saxagliptin
versus placebo as add-on therapy to metformin) [12],
and −0.74% (52-week trial of saxagliptin versus glipizide
as add-on therapy to metformin) [17]; and between-
group differences in adjusted mean change from baseline
HbA1c (95% CI) were 0.09% (−0.01% to 0.20%), −0.83%
(−1.02% to −0.63%), and 0.06% (−0.05% to 0.16%), respect-
ively. In these same 3 studies, adjusted mean changes from
baseline FPG were −10.8, −22.0, and −9 mg/dL, respect-
ively. In the current study, adjusted mean change from
baseline HbA1c was −0.56% with saxagliptin 2.5 mg
BID in combination with metformin IR BID, and the
mean (SE) between-group difference was −0.34% (0.12%).
To further place these findings in context, the UK Pro-
spective Diabetes Study Group demonstrated a 37%
Table 4 Most common adverse events occurring in ≥2%
of patients (treated patients population)
AE, n (%) Saxagliptin +
Metformin (n = 74)
Placebo +
Metformin (n = 86)
Hypoglycemia
All reported 4 (5.4) 1 (1.2)
Confirmed 0 1 (1.2)
Infections and
infestations
5 (6.8) 11 (12.8)
Bronchitis 1 (1.4) 2 (2.3)




4 (5.4) 8 (9.3)
Back pain 2 (2.7) 3 (3.5)
Muscle spasms 1 (1.4) 3 (3.5)
Gastrointestinal
disorders
3 (4.1) 6 (7.0)




Lymphadenopathy 2 (2.7) 0
Vascular disorders 2 (2.7) 3 (3.5)
Hypertension 2 (2.7) 2 (2.3)
Nervous system
disorders
2 (2.7) 5 (5.8)
Dizziness 2 (2.7) 0




2 (2.7) 3 (3.5)
Sinus congestion 1 (1.4) 2 (2.3)
Hepatobiliary disorders 1 (1.4) 2 (2.3)
Cholecystitis 0 2 (2.3)
Psychiatric disorders 0 2 (2.3)
Insomnia 0 2 (2.3)
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1% reduction in HbA1c [23]. Although HbA1c is consid-
ered an appropriate surrogate marker for microvascular
outcomes [24], macrovascular risk reduction was not an
end point in the current study.
In a previous trial of saxagliptin plus metformin IR as
initial combination therapy, significantly greater effective-
ness versus the individual monotherapies was demon-
strated for reduction of HbA1c (2.5% reduction vs 1.7% and
2.0% for saxagliptin and metformin alone, respectively) and
FPG (reduction of 60 mg/dL vs 31 mg/dL and 47 mg/dL
for saxagliptin and metformin alone, respectively) [18].
In the current study, reductions in placebo-adjusted
FPG, though of similar magnitude with the statistically sig-
nificant reductions in FPG with saxagliptin add-on therapyin other studies, did not reach statistical significance. This
precluded formal assessment of the proportions of patients
achieving HbA1c targets. However, the proportions of
patients achieving HbA1c <7% or ≤6.5% were numeric-
ally greater for the saxagliptin plus metformin group
compared with the placebo plus metformin group and
consistent with previous short-term studies of saxagliptin
added to metformin or existing oral antihyperglycemic
therapy (HbA1c <7% range, 22.8%–43.5%) [12,14,25,26].
Because lowering HbA1c to ≤7% has been demonstrated
to reduce microvascular complications [24], this end point
provides further context regarding the clinical relevance
of glycemic improvement in this study.
The low rate of hypoglycemic events and small change
in body weight observed in this BID dosing study are con-
sistent with those observed in previous studies [12,15-18].
GI AEs were not exacerbated with respect to incidence or
severity by the addition of saxagliptin. Overall, the present
study provides reassurance of the safety and tolerability of
saxagliptin plus metformin when both are given as divided
BID doses.
We acknowledge several limitations of this study, in-
cluding the 12-week timeframe and the relatively small
sample size. As there is known interindividual variability
in red blood cell lifespan [27], 12 weeks may not be suffi-
cient to demonstrate the full potential for HbA1c lowering
in a study population. The absence of statistical signifi-
cance of the first prespecified secondary end point of FPG
precluded further sequential assessment for statistical sig-
nificance of other key secondary end points. Because FPG
has greater biologic and analytic variability than HbA1c
[28], this study may not have been powered to detect
changes in FPG. However, other categorical measures of
glycemic control were numerically improved with saxa-
gliptin given twice daily, supporting the demonstration of
improved glycemic control compared with placebo when
added to metformin. Inclusion criteria necessarily limited
the heterogeneity of the study population, which could
affect generalizability. Although there are ethical concerns
regarding placebo-controlled designs, this approach was
important for initial evaluation of this new regimen of sax-
agliptin administration in order to evaluate the potential
bias of clinical study participation. The trial was limited to
12 weeks in duration, and patients were discontinued
from treatment and withdrawn from the study if they had
lack of glycemic control during the double-blind treat-
ment period at weeks 4 and 8. An active-controlled study
may provide important further information about the clin-
ical utility of this regimen.
Conclusions
In patients with type 2 diabetes and inadequate glycemic
control on metformin monotherapy, the addition of
saxagliptin, a medication with a mechanism of action
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http://www.biomedcentral.com/1472-6823/14/17complementary to metformin [29], significantly reduced
HbA1c compared with the addition of placebo. The
present study demonstrates that saxagliptin 2.5 mg BID
added to ongoing metformin IR BID was effective in re-
ducing HbA1c levels compared with placebo, with a
similar AE profile and no unexpected safety findings.
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